Speaker illustration

Doctor Janice Chew-Harris

University of Otago Christchurch, Christchurch (New Zealand)

Member of:

European Society of Cardiology

Dr Janice Chew-Harris received her PhD degree from University of Otago in Christchurch, New Zealand at the end of 2016. Her research is focused on measurements and detection of novel plasma and urinary biomarkers. Her current research aims to assess the performances of biomarkers and their prognostic abilities in predicting risk, earlier detection and in guiding therapy, in both acute and progressive forms of cardiac and renal diseases. She is also interested in studies relating to mechanisms and modulation of cardiorenal syndromes. She has previously worked as a medical laboratory scientist (Clinical Biochemistry) and is trained in many advanced laboratory methods.

Prognostic performance of soluble urokinase plasminogen activator receptor for 1-year mortality in Asian and Western patients with acute breathlessness

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Biomarkers

Session: Novel Biomarkers for Early Risk Stratification in Acute Heart Failure

Thumbnail

Soluble urokinase plasminogen activator receptor (suPAR) predicts 2-year cardiovascular events in patients after acute chest pain

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Biomarkers

Session: Acute Coronary Syndromes ePosters

Thumbnail

Soluble urokinase plasminogen activator receptor (suPAR) can predict long-term mortality in patients with acute chest pain

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Biomarkers

Session: Acute Coronary Syndromes ePosters

Thumbnail

Soluble urokinase plasminogen activator receptor (suPAR) predicts 1 year mortality in patients with acute breathlessness

Event: ESC CONGRESS 2019

Topic: Biomarkers

Session: Acute heart failure 1

Thumbnail

Soluble urokinase plasminogen activator receptor (suPAR) predicts 2-year cardiovascular events in patients after acute chest pain

Event: ESC Asia with APSC & AFC 2020

Topic: Biomarkers

Session: Abstract Programme

Thumbnail

Soluble urokinase plasminogen activator receptor (suPAR) can predict long-term mortality in patients with acute chest pain

Event: ESC Asia with APSC & AFC 2020

Topic: Biomarkers

Session: Abstract Programme

Thumbnail

Prognostic performance of soluble urokinase plasminogen activator receptor for 1-year mortality in Asian and Western patients with acute breathlessness

Event: ESC Asia with APSC & AFC 2020

Topic: Biomarkers

Session: Abstract Programme

Thumbnail

This platform is supported by

logo Novo Nordisk